News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Clinical - Phase II
Sunovion Initiates SEP-363856 Phase II Program For Patients With Schizophrenia Or Parkinson’s Disease Psychosis 12/2/2016
Ignyta (RXDX) Release: Late-Breaking Oral Plenary Presentation Of A Novel Entrectinib Combination Regimen At The 2016 EORTC-NCI-AACR Annual Meeting 12/2/2016
Promedior Announces Completion Of Patient Enrollment Milestones In Phase 2 Clinical Studies Of PRM-151 In Both Idiopathic Pulmonary Fibrosis And Myelofibrosis 12/2/2016
Heat Biologics Presents Topline HS-410 Phase II Bladder Cancer Results At The Society Of Urological Oncology Annual Meeting 12/1/2016
Acadia (ACAD) Initiates Phase II Trial Of Pimavanserin For Adjunctive Treatment In Patients With Major Depressive Disorder 12/1/2016
Agilis Biotherapeutics Announces Orphan Designation Approval In Europe For The Treatment Of AADC Deficiency 12/1/2016
Aicuris Announces Start Of Lipp 1: First Subject Enrolled In The Clinical Phase 2 Trial With Topical Pritelivir For The Treatment Of Recurrent Labial Herpes 12/1/2016
CytRx (CYTR) Plans to File NDA for Once-Failed Sarcoma Drug While Columnist Raises Questions Over Efficacy and CEO Salary Amid Struggle 11/30/2016
Oncoquest Announces Positive Interim Results From Its Phase IIb Clinical Study 11/30/2016
Biothera Announces Data Demonstrating Unique Immune Response Profile Generated By Phase 2 Cancer Immunotherapy Imprime PGG 11/30/2016
Agenus (AGEN) Announces Commencement Of Phase 1/2 Clinical Trial Of Anti-OX40 Checkpoint Antibody INCAGN1949 In Patients With Solid Tumors 11/30/2016
Achillion (ACHN) Announces Initiation Of Patient Dosing By Janssen Pharmaceutical In A Global, Short Treatment-Duration Phase 2b Study Of JNJ-4178 In Chronic HCV 11/30/2016
Cerecor (CERC) Tanks as Lead Depression Drug Flops in Mid-Stage Study 11/30/2016
Dynavax (DVAX) To Present Clinical Data From Immuno-oncology Product Candidate, SD-101 11/30/2016
Latest Deaths in Juno (JUNO) Trial Puts Unwanted Limelight on the FDA 11/29/2016
BerGenBio AS Reports Promising BGB324 Phase I/II Monotherapy Data In Patients With Lung Cancer At The EORTC-NCI-AACR Molecular Targets And Cancer Therapeutics Symposium 11/29/2016
Eyenovia Announces Publication Of Phase II Study Results Demonstrating Benefits Of Micro-Formulation Over Conventional Eyedroppers And Addition Of Scientific Advisory Board Members 11/29/2016
Windtree Therapeutics (WINT)' AEROSURF (Lucinactant For Inhalation) Phase 2a Data Presented At The 2016 International Congress Of Union Of European Neonatal And Perinatal Societies 11/29/2016
Vtesse Receives Rare Pediatric Disease Designation By The FDA For VTS-270 For The Treatment Of Niemann-Pick Type C1 Disease 11/29/2016
Eiger Biopharma Updates Progress In Clinical Development Program For Exendin 9-39 To Treat Post-Bariatric Hypoglycemia (PBH) 11/29/2016
BiondVax Pharmaceuticals Phase 2b Trial Preliminary Safety Results: The Universal Flu Vaccine Candidate Is Safe And Well Tolerated 11/29/2016
Nivalis (NVLS) Decimated as Cystic Fibrosis Drug Flops in Mid-Stage Study 11/29/2016
Pharmalink AB Announces European Orphan Drug Designation For Nefecon For Treatment Of Iga Nephropathy, An Inflammatory Kidney Disease 11/29/2016
Investors Remain Bullish Over Biogen (BIIB)'s Risky Alzheimer's Drug Despite Eli Lilly (LLY) Setback 11/28/2016
Juno (JUNO) Halts CAR-T Trial for Second Time Following Additional Patient Deaths 11/28/2016
Nanobiotix Provides Update On Global Development Of Lead Product NBTXR3 11/28/2016
GTx, Inc. (GTXI) Release: Enobosarm Meets Pre-Specified Primary Efficacy Endpoint In Ongoing Phase 2 Clinical Trial In ER+/AR+ Breast Cancer 11/28/2016
Medivir (MVRBF) Announces That Janssen Has Initiated An Open-Label Phase IIb Study Of The 3DAA Combination Of Simeprevir, Odalasvir And AL-335 (JNJ-4178) 11/28/2016
Nature Cell Receives U.S. FDA Approval For Phase I And II Alzheimer's Clinical Trial 11/28/2016
Araim Pharmaeuticals Release: ARA 290 Obtains European Union Orphan Drug Designation For Prevention Of Graft Loss In Pancreatic Islet Transplantation 11/28/2016
Global Blood Therapeutics (GBT) Announces Initiation Of Phase IIa Trial Of GBT440 In Idiopathic Pulmonary Fibrosis (IPF) 11/28/2016
The Franchise That Could Bring in Another $20 Billion for Celgene (CELG) 11/23/2016
5 Drug Giants That Could Dominate the $13 Billion Alzheimer's Market 11/23/2016
New Data On Zogenix (ZGNX)’s ZX008 For Lennox Gastaut Syndrome & Dravet Syndrome To Be Presented At 70th Annual American Epilepsy Society Meeting 11/23/2016
Ability Pharma Initiates Phase 2 Combination Trial With ABTL0812 As First Line Therapy In Patients With Endometrial Or Squamous Lung Cancer Patients 11/22/2016
Investors Upset as Acorda (ACOR) Abandons Development of Another Drug After Phase II Flop 11/22/2016
Neurotrope Completes Enrollment In Its Randomized, Double-Blinded, Placebo-Controlled Phase 2 Clinical Trial Of Bryostatin In Patients With Moderate To Severe Alzheimer's Disease 11/22/2016
Viral Gene Announces Breakthrough In Colon Cancer: New Vaccine Targets Enzyme To Help Destroy Metastatic Tumor Cells 11/22/2016
Merck & Co. (MRK) Release: New KEYTRUDA (Pembrolizumab) Data In Blood Cancers To Be Presented At 58th Annual Meeting Of The American Society of Hematology 11/22/2016
Opthea Completes Patient Enrolment In Phase 1/2A Wet AMD Clinical Trial 11/22/2016
U.S. FDA Grants Fast Track Designation For The Development Of Oragenics (OGEN)’ AG013 For Oral Mucositis 11/21/2016
Ligand (LGND) Partner Retrophin (RTRX) Reports Additional Positive Data From Phase 2 DUET Study Of Sparsentan In Focal Segmental Glomerulosclerosis At American Society of Nephrology Kidney Week 2016 11/21/2016
Acorda (ACOR) To Discontinue Development Of Dalfampridine For Treatment Of Post-Stroke Walking Difficulties 11/21/2016
Kadmon To Present Additional Data Demonstrating Tesevatinib Safety For The Treatment Of Polycystic Kidney Disease At American Society of Nephrology Kidney Week 2016 11/21/2016
ImmunoCellular Therapeutics, Ltd (IMUC) Reports Updated Immune Monitoring Data From ICT-107 Phase 2 Trial In Newly Diagnosed Glioblastoma At The Society For Neuro-Oncology Annual Meeting 2016 11/21/2016
Partial Clinical Hold Lifted and Enrollment Resumes for Aduro Biotech (ADRO) LADD Clinical Trials 11/21/2016
Mallinckrodt (MNK) Will Initiate Company-Sponsored Clinical Trial Of H.P. Acthar Gel In Treatment Of Amyotropic Lateral Sclerosis (ALS) 11/21/2016
DelMar Pharma Delivers An Address And Presents An Overview Of Upcoming GBM Trials With VAL-083 At The CNS Anticancer Drug Discovery Development Conference And Society For NeuroOncology Annual Meeting 11/21/2016
Matinas BioPharma Initiates Enrollment And Commences Patient Dosing In Phase II Study Of MAT2203 For The Treatment Of Vulvovaginal Candidiasis 11/21/2016
Retrophin (RTRX) Reports Additional Positive Data From Phase II DUET Study Of Sparsentan In Focal Segmental Glomerulosclerosis At American Society of Nephrology Kidney Week 2016 11/21/2016
Aurinia (ISA.TO) Highlights Renal Function Data From Global Phase IIb AURA Study Of Voclosporin For Lupus Nephritis At American Society of Nephrology Kidney Week 2016 11/21/2016
Kite Pharma (KITE) To Present Interim Results From The ZUMA-1 Pivotal Trial Of KTE-C19 In A Late-Breaking Session At The 2016 American Society of Hematology Annual Meeting 11/21/2016
BioSpecifics Technologies Corporation (BSTC) Announces Positive Data From Phase 2b Study Of CCH In Patients With Cellulite 11/18/2016
Stealth Biotherapeutics Announces Positive Phase 2 Clinical Trial Findings For Patients Undergoing Renal Angioplasty 11/18/2016
Investors Hold Their Breath for the "Most Important Event in Biotech"—Here are 5 Stocks to Watch 11/18/2016
ProMetic Life Sci (PFSCF.PK)'s PBI-4050 Demonstrates Early Evidence Of Efficacy In Its Idiopathic Pulmonary Fibrosis ("IPF") Phase 2 Clinical Trial 11/17/2016
Endo International (ENDP) Announces Positive Data From Phase 2b Study Of Collagenase Clostridium Histolyticum (CCH) In Patients With Cellulite 11/17/2016
Catabasis (CATB) Provides Edasalonexent And Rare Disease Pipeline Updates At Investor Day 11/17/2016
Reviva Pharma Receives FDA Orphan Designation For Pulmonary Arterial Hypertension (PAH) 11/17/2016
NW Bio (NWBO) Announces Phase II Clinical Trial Program Combining DCVax-L And Pembrolizumab (Keytruda) For Colorectal Cancer 11/17/2016
Positive Results From Study Sponsored By CardioCell Post In The AHA's Journal "Circulation Research" 11/17/2016
Dermata Therapeutics Announces Initiation Of Treatment In A Phase 2 Atopic Dermatitis Study 11/17/2016
Agilis Biotherapeutics Achieves FDA "Rare Pediatric Disease" Designation For AADC Gene Therapy Candidate 11/17/2016
Ariad (ARIA) Announces Data Presentations At The World Conference On Lung Cancer 11/17/2016
AzurRx BioPharma (AZRX) And Mayoly Spindler Announce Initiation Of Phase II Clinical Trial Of MS1819-SD For Exocrine Pancreatic Insufficiency In Chronic Pancreatitis Patients 11/17/2016
Puma Biotech (PBYI) Crashes After Diarrhea Risk is Linked to Breast Cancer Drug in Abstract 11/16/2016
ProMetic Life Sci (PFSCF.PK) Receives Clearance From Health Canada To Proceed With Its PBI-4050 Placebo-Controlled Phase 2 Clinical Trial In Patients With Metabolic Syndrome And Type 2 Diabetes 11/16/2016
CytoDyn (CYDY)’s Two-Year Update On Its PRO 140 Monotherapy Study In HIV Accepted At CROI 2017 11/16/2016
Heat Biologics To Present Topline HS-410 Phase II Bladder Cancer Results At The Society Of Urological Oncology Annual Meeting 11/16/2016
Aurinia (ISA.TO) Highlights Speed Of Remission From Global Phase IIb AURA Study Of Voclosporin In Lupus Nephritis At 2016 American College of Rheumatology Annual Meeting 11/16/2016
Genexine Co. Ltd. Granted FDA Orphan Drug Designation For GX-H9 In Growth Hormone Deficiency 11/16/2016
SAGE Therapeutics (SAGE) Release: SAGE-547 Granted PRIME Designation By EMA For The Treatment Of Postpartum Depression 11/16/2016
Agilis Biotherapeutics Announces First Patient Treated In Phase IIb Clinical Study Of Gene Therapy For AADC Deficiency 11/16/2016
GTX Corp Achieves Second Stage 1 Milestone In Phase 2 Clinical Trial Of Enobosarm In ER+/AR+ Breast Cancer 11/16/2016
Tiziana Life Sciences Plc Announces New Data With Foralumab, A Fully Human Anti-CD3 Antibody Being Developed As An Oral Therapy For NASH And Autoimmune Diseases 11/16/2016
CSL Behring Presents Positive Results from the CSL112 AEGIS-I Phase IIb Trial 11/15/2016
Janssen R&D Next-Generation Biologic Guselkumab Shows Promise In The Treatment Of Psoriatic Arthritis In Phase 2 Trial 11/15/2016
Eiger Biopharma Announces Additional LOWR HDV Program Data, Clinical And Regulatory Plans At The American Association for Study of Liver Diseases Meeting 11/15/2016
Albireo (ALBO)’s Lead Product Candidate For Orphan Pediatric Liver Disease Accepted Into EMA's PRIME Program 11/15/2016
Merck KGaA (MKGAF.PK)'s Atacicept Flops in Phase IIb Lupus Study But Firm Remains Upbeat 11/15/2016
Karolinska Development AB Company Modus Therapeutics’ Ongoing Clinical Study With Sevuparin In Sickle Cell Disease Expands To Include Adolescent Patients 11/15/2016
MorphoSys AG Announces That Its Licensee Janssen Has Presented Positive Clinical Data Of Guselkumab In Psoriatic Arthritis 11/15/2016
Gilead (GILD) Release: Phase 2 Data For Selonsertib In Nonalcoholic Steatohepatitis (NASH) Presented At The Liver Meeting 2016 11/15/2016
Ionis Pharma (IONS) Reports Positive Clinical Data From IONIS-ANGPTL3-L Rx 11/15/2016
NantKwest Announces Achievement Of End Point In Merkel Cell Carcinoma Phase II Trial With Evidence Of Efficacy Of Activated Natural Killer (Ank) Cells In Solid Tumors 11/15/2016
Repros Therapeutics (RPRX) Reports Topline Positive Clinical Data After Two 18 Week Courses Of Proellex Delivered Orally And Vaginally For The Treatment Of Uterine Fibroids 11/15/2016
Acadia (ACAD) Initiates Phase II Trial Of Pimavanserin For Adjunctive Treatment In Patients With Negative Symptoms Of Schizophrenia 11/15/2016
The Medicines Company (MDCO) And Alnylam (ALNY) Present Positive Results From ORION-1 Phase II Study Of Inclisiran (formerly PCSK9si) 11/15/2016
CytRx (CYTR) Presents Positive Interim Results From On-Going Phase 1b/2 Aldoxorubicin Combination Clinical Trial At The 2016 CTOS Annual Meeting 11/14/2016
Eiger Biopharma Announces Positive Phase 2 Data At The American Association for Study of Liver Diseases Meeting: Multiple Paths Forward Identified With Lonafarnib Therapy In LOWR HDV Program 11/14/2016
Reata Pharmaceuticals, Inc. Announces Plan for Global Phase II/III Trial in Chronic Kidney Disease Caused by Alport Syndrome 11/14/2016
OncoSec Medical Presents Positive Interim Response Data At The Society For Immunotherapy Of Cancer (SITC) Annual Meeting 2016 11/14/2016
Zytoprotec GmbH Phase II Peritoneal Dialysis Study: Last Patient Out 11/14/2016
Little Corbus (CRBP) Gains Close to $180 Million in Market Cap on Mid-Stage Systemic Sclerosis Data 11/14/2016
Provectus Announces Poster Presentation On PV-10 At Society For Immunotherapy Of Cancer 2016 Annual Meeting 11/14/2016
Takeda (TKPYY) Release: Results Of Study Of Febuxostat On The Frequency Of Acute Gout Flares In Early Gout 11/14/2016
Merck & Co. (MRK) Announces Findings For Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates Of Sustained Virologic Response In People With Genotypes 1, 2 Or 3 Infection 11/14/2016
Bristol-Myers Squibb (BMY) Release: Opdivo (Nivolumab) And Yervoy (Ipilimumab) Regimen Shows Promising Efficacy And Safety In Previously Treated Patients With Advanced Form Of Bladder Cancer 11/14/2016
Bristol-Myers Squibb (BMY) Release: Interim Phase 1/2 Data Show Encouraging Clinical Benefit For Lirilumab In Combination With Opdivo (Nivolumab) In Patients With Advanced Platinum Refractory Squamous Cell Carcinoma Of The Head And Neck 11/14/2016
3 Reasons That Make Biogen (BIIB) the King of a Crumbling Empire 11/14/2016
New Immune Design Corporation (IMDZ) Data Highlights Expanded Product Potential Of Zvex® Platform At The 2016 SITC Annual Meeting 11/11/2016
Spotlight Innovation Subsidiary Celtic Biotech Iowa Receives Approval To Commence Phase I Part 2 Clinical Trial Of Crotoxin 11/11/2016
Symic Biomedical And Nordic Bioscience A/S Complete Enrollment Of MODIFY-OA Trial Of SB-061 For The Treatment Of Osteoarthritis 11/11/2016
Capricor Therapeutics, Inc. Announces Plans To Expand Clinical Development Program In Duchenne Muscular Dystrophy To Evaluate Peripheral And Respiratory Muscle Function 11/11/2016
Biothera Preclinical Data Further Validate Mechanism Of Its Phase II Cancer Immunotherapy, Imprime PGG 11/11/2016
Wilson Therapeutics Presents Updated Preliminary Clinical Data On WTX101 At The American Association for Study of Liver Diseases Liver Meeting 11/11/2016
Enanta Pharmaceuticals, Inc. Announces Eight Weeks Of Treatment With AbbVie (ABBV)’s Investigational, Pan-Genotypic Regimen Of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR Rates Across All Major Genotypes Of Chronic Hepatitis C 11/11/2016
Aldeyra (ALDX) Announces Presentation Of Phase 2 Allergic Conjunctivitis Results At The 2016 American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting 11/10/2016
Tonix Pharma (TNXP) To Present New Clinical Results From Retrospective Analysis Of Phase II AtEase Study In Military-Related PTSD 11/10/2016
The Medicines Company (MDCO) To Host Conference Call And Webcast To Review Data From Ongoing ORION-1 Phase II Study Of PCSK9si 11/10/2016
Elcelyx Therapeutics Reports Positive Results In Phase 2b Study Of Metformin Delayed Release In Type 2 Diabetes 11/10/2016
AstraZeneca PLC (AZN) Faces Another R&D Setback as Plans to File for Early Approval for Cancer Med are Scrapped 11/10/2016
FDA Slaps Clinical Hold on Arrowhead Pharma (ARWR)'s Hep B Study 11/9/2016
Dynavax (DVAX) Presents Early Clinical Data From Lead Cancer Immunotherapy Candidate, SD-101, At Society For Melanoma Research 11/9/2016
Imago Biosciences Enrolls First Patient In Phase 1/2 Study Of IMG-7289 In Acute Myeloid Leukemia And Myelodysplastic Syndrome 11/9/2016
OncoSec Medical Announces Positive Interim Response Data At The Society For Immunotherapy Of Cancer (SITC) Annual Meeting 2016 11/9/2016
FDA Slaps a Full Clinical Hold on BioInvent (BOVNF)'s Phase II Multiple Myeloma Study 11/8/2016
Sirnaomics Received Green Light From US FDA For A Clinical Phase IIa Study Of Its Leading Sirna Therapeutic Candidate, STP705, For Treatment Of Hypertrophic Scar 11/8/2016
The Medicines Company (MDCO) Abandons Development of Plaque Buster MDCO-216; Will Dump Cash Into PCSK9 Instead 11/8/2016
DBV Tech Completes Enrollment Of Phase II Study Of Viaskin Milk For The Treatment Of Milk Allergic Patients 11/8/2016
Cerenis Therapeutics, Inc. Announces Last Patient Dosed In CARAT Phase II Study With CER-001 In Post-Acute Coronary Syndrome Patients 11/8/2016
Ascend Biopharmaceuticals Announces Encouraging Phase I/IIa Interim Results Of ASN-002 Treatment Of Nodular Basal Cell Carcinoma (nBCC) 11/8/2016
Neovacs Enrolls The First U.S. Patient In Phase IIb Study Of Ifna Kinoid For Treatment Of Systemic Lupus Erythematosus (SLE) 11/7/2016
Immunovative Therapies, Ltd. Release: CryoVax : Next Generation Immunotherapy For Metastatic Colorectal Cancer Begins USA Phase IIb Clinical Trial 11/7/2016
Gilead (GILD) Drops Another Bombshell, Will Shift R&D Cash Away From Hep C 11/7/2016
Safety Review Committee For Nordic Nanovector's Lymrit 37-01 Trial Recommends Dose Escalation To 20 MBq/kg With Betalutin 11/4/2016
BeyondSpring Pharmaceuticals Clinical Data On Neutropenia Mitigation With Plinabulin To Be Presented At 2016 American Society of Hematology Annual Meeting 11/4/2016
Sanofi (SNY) and Novartis AG (NVS) are the Worst Culprits in Reporting Clinical Trial Data, Shire (SHPG) the Best 11/4/2016
Lycera Announces Publication Of Immuno-Oncology Research, Demonstrating Differentiated Mechanism Of RORgamma Agonists 11/4/2016
Rhythm Presents Positive Initial Data For Setmelanotide In LepR Deficiency Obesity 11/4/2016
GENFIT (ALGFT): FDA Has Officially Cleared The IND To Proceed With Phase II Trial And Evaluate Elafibranor In PBC 11/4/2016
Four Patients Suffered Serious Adverse Events While on Roche (RHHBY)'s Breakthrough Hemophilia Drug 11/3/2016
One Out of the Two Reasons Allergan (AGN) Paid $640 Million for Vitae Pharma (VTAE) Just Flunked Mid-Stage Test 11/3/2016
Helsinn And MEI Pharma (MEIP) Announce Long-Term Survival And Response Data From Phase II Clinical Study Of Pracinostat In Acute Myeloid Leukemia Accepted For Oral Presentation At Upcoming American Society of Hematology Annual Meeting 11/3/2016
Mast Therapeutics (MSTX) Release: Positive Interim Results From Phase 2 Study Of AIR001 In Patients With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction (PH-Hfpef) Published In Journal Of Clinical Investigation 11/3/2016
Sanofi Genzyme (SNY) Release: Pivotal Phase 2/3 Trial Of Olipudase Alfa For Adult Patients With Acid Sphingomyelinase Deficiency (Niemann-Pick Disease Type B) To Begin In The UK 11/3/2016
BioLineRx Discloses Positive Correlative Data From Phase 2a AML Study And Mechanism-Of-Action Data For BL-8040 Oncology Platform At American Society of Hematology 2016 11/3/2016
Karyopharm (KPTI) To Present Updated Phase IIb STORM And Phase Ib STOMP Clinical Data At The American Society of Hematology 2016 Annual Meeting 11/3/2016
Towards The Company's First Clinical Trial; Kadimastem Signs Letter Of Intent With Hadassah Medical Center For Performance Of The Clinical Trial In ALS 11/3/2016
Nordic Nanovector: Updated Results From Phase 1/2 Trial Of Betalutin In Non-Hodgkin Lymphoma To Be Presented At American Society of Hematology Annual Meeting In December 11/3/2016
Santalis Obtains FDA Allowance To Start A Phase 2 Clinical Study For The Treatment Of Mild To Moderate Atopic Dermatitis (AD) 11/3/2016
Revance (RVNC) Announces Initiation Of Phase II Trial Of RT002 Injectable To Treat Plantar Fasciitis 11/3/2016
Merck & Co. (MRK)'s Alzheimer's Contender Wows in Human Clinical Trial 11/3/2016
Gilead (GILD) Looking Even Weaker on the R&D Front as It Racks Up Some More Clinical Failures in Q3 Report 11/2/2016
The $40 Billion NASH Market and the 3 Biotechs That Stand to Profit From it 11/2/2016
10 Drugs That Could be Johnson & Johnson (JNJ)'s New Blockbusters 11/2/2016
DNAtrix, Inc. Announces First Patients Treated In Phase 2 Trial With DNX-2401 And KEYTRUDA 11/2/2016
Kamada Ltd. (KMDA) Announces Plan For Phase II/III Clinical Trial With Alpha-1 Antitrypsin IV For Treatment Of Graft-Versus-Host Disease 11/2/2016
Zynerba (ZYNE) Announces Initiation Of STAR 2 Open-Label Extension Clinical Trial For ZYN002 CBD Gel In Adult Refractory Epilepsy Patients 11/2/2016
Merck KGaA (MKGAF.PK), Darmstadt, Germany, Presents Phase II Data On The Safety And Efficacy Of Atacicept At The 2016 ACR/ARHP Annual Meeting 11/2/2016
Omeros (OMER) Announces Positive Data From Phase 2 Clinical Trial Evaluating PPAR-Gamma Agonist In Heroin Users Treated With Buprenorphine/Naloxone 11/2/2016
University of California, Irvine Doses First Patient In Phase IIa Clinical Trial Using Stemedica's Stem Cells For Alzheimer's Disease 11/1/2016
Ionis Pharma (IONS) Reports Positive Phase 2 Data For IONIS-FXI Rx In Patients With End-Stage Renal Disease On Hemodialysis 11/1/2016
Axim Biotech Begins PK/PD Studies With CanChew Plus CBD Gum For IBS Symptoms In Suffering Patients 11/1/2016
Renova Therapeutics Announces Successful End-Of-Phase 2 Meeting With FDA For RT-100 AC6 Gene Transfer Therapy 11/1/2016
Castle Creek Pharma Continues To Build Executive Team As Company Secures Funding, Positive Phase II Results 11/1/2016
Eisai Inc. (ESALF.PK) Initiates Phase 2 Clinical Trial To Evaluate Lemborexant In The Treatment Of Irregular Sleep-Wake Rhythm Disorder (ISWRD) In Dementia Patients 10/31/2016
Cellectar Biosciences  (CLRB) Announces Design For NCI-Supported Phase II Study Of CLR 131 In Multiple Myeloma And Other Hematologic Malignancies 10/31/2016
Acadia (ACAD) Initiates Phase II Study Of Pimavanserin In Alzheimer’s Disease Agitation 10/31/2016
Theravance Biopharma (TBPH) Presents Interim Data From Ongoing Telavancin Observational Use Registry (TOUR) At IDWeek 2016 10/31/2016
Omeros (OMER) Requests Fast Track Designation For OMS721 For The Treatment Of IgA Nephropathy 10/31/2016
Ophthotech (OPHT) Announces The Publication Of Fovista In Combination With Lucentis Phase 2b Study Results In Ophthalmology, The Journal Of The American Academy of Ophthalmology 10/31/2016
Opexa Therapeutics (OPXA)' Stock Slammed After MS Candidate Flunks Phase II Test 10/28/2016
Entasis To Present Data At IDWeek On ETX2514SUL, A Novel Drug Targeting Multidrug-Resistant Acinetobacter Baumannii Infections 10/28/2016
Why Biogen (BIIB)'s Fate May Depend on Eli Lilly (LLY)'s Alzheimer's Data 10/27/2016
Abbott (ABT) Release: New Study: Babies Fed Infant Formula With 2'-FL Human Milk Oligosaccharide+ Had Immune Response More Like Breastfed Babies 10/27/2016
Results From Shire (SHPG)'s Phase 2 Study Of Maribavir Showed Activity Against CMV Infection In Patients Undergoing Transplant 10/27/2016
Medivir (MVRBF): MIV-711 Osteoarthritis Program: Enrollment In The Phase IIa Study Is Complete And Independent Safety Review Committee Again Recommends Go Ahead 10/27/2016
DBV Tech Announces Publication Of Positive Viaskin Peanut Data From NIAID-Sponsored Phase II Academic Study In The Journal Of Allergy And Clinical Immunology 10/27/2016
OncoGenex (OGXI) Announces Positive Survival Results From Apatorsen Phase 2 Borealis-2 Trial In Metastatic Bladder Cancer 10/26/2016
ProMetic Life Sci (PFSCF.PK)'s Plasminogen Meets Primary And Secondary End Points In Pivotal Phase 2/3 Trial 10/26/2016
Vertex (VRTX) to Test Next-Generation CF Drugs by End of Year 10/26/2016
National Center for Child Health And Development Initiates Phase 1/2 Trial Of Green Cross' Idursulfase-Beta ICV For The Treatment Of Hunter Syndrome With Neurocognitive Decline 10/26/2016
Vertex (VRTX) Announces Planned Initiation Of Phase 2 Studies Evaluating The Next-Generation Correctors VX-440 And VX-152 In Triple Combination Regimens To Treat The Underlying Cause Of Cystic Fibrosis 10/26/2016
Daiichi Sankyo Release: Anti-HER3 Monoclonal Antibody Patritumab Selected For I-SPY 2 TRIAL In Breast Cancer 10/25/2016
Eurocine Vaccines Announces Initiation Of Clinical Study Of The Nasal Influenza Vaccine Candidate Immunose FLU 10/25/2016
Lexicon Pharma (LXRX) Reports Positive Top-Line Results In Phase 2 Dose-Ranging Study For Sotagliflozin In Patients With Type 1 Diabetes 10/25/2016
Windtree Therapeutics (WINT) Releases Data From Lung Deposition Study In Non-Human Primates Demonstrating Uniform Distribution Of Aerosolized KL4 Surfactant In All Regions Of The Lung 10/25/2016
Stealth Biotherapeutics Initiates Phase 2 Study Of Elamipretide In Patients Hospitalized With Congestive Heart Failure 10/25/2016
Debiopharm Reaches Important Development Milestones For Its Staphylococcus-Selective Antibiotic Debio 1450 10/25/2016
Bristol-Myers Squibb (BMY) Release: New Results Presented For Opdivo (Nivolumab) Demonstrate Encouraging Response Rate In An Expanded Population Of Heavily Pre-Treated Classical Hodgkin Lymphoma Patients 10/25/2016
Debiopharm Reaches Important Development Milestones For Its Staphylococcus-Selective Antibiotic Debio 1450 10/25/2016
aTyr Pharma Receives FDA Fast Track Designation For Resolaris To Treat Facioscapulohumeral Muscular Dystrophy (FSHD) 10/24/2016
Advaxis (ADXS) Announces GOG-0265 12-Month Overall Survival Rate Of 37.5% In Stage 2 10/24/2016
Cidara (CDTX) Announces Data From Studies Of Novel Antifungal CD101 To Be Presented At ACCP And IDweek Annual Meetings 10/24/2016
A Look at BioMarin (BMRN)'s Potential Blockbuster and the Science Behind It All 10/21/2016
Roche (RHHBY)'s Avastin Successor Flunks Key Study, Turns Hope to Tecentriq Instead 10/21/2016
PTC Therapeutics (PTCT) Release: Spinal Muscular Atrophy Program Advances Into Phase 2 Clinical Studies In SMA Patients With RG7916 10/21/2016
Dermira (DERM) Presents Data From DRM01 Phase IIb Clinical Program At Annual Meeting For Dermatologists 10/21/2016
Alkermes (ALKS)' Success Puts the Spotlight on Cerecor, Eli Lilly (LLY)'s 2015 Deal 10/21/2016
What You May Have Missed: Critics Point to Problems With Celgene (CELG)’s Crohn’s Drug Trial Design 10/20/2016
First Patient Cohort Data From BioTime (BTX)'s OpRegen Clinical Trial In Dry-AMD To Be Presented At ISOPT Clinical Symposium On December 2, 2016 10/20/2016
Alexion (ALXN) Release: FDA Grants Orphan Drug Designation To ALXN1007 For The Treatment Of Patients With Graft-Versus-Host Disease (GVHD) 10/20/2016
ProMetic Life Sci (PFSCF.PK)'s PBI-4050 Meets Primary And Secondary End Points In Metabolic Syndrome And Type 2 Diabetes Phase 2 Clinical Trial 10/20/2016
HedgePath Pharmaceuticals Announces Further Positive Interim Data In Its Phase II(B) Cancer Trial 10/20/2016
Sanifit Announces Initiation Of First Clinical Trial Of SNF472 In Patients With Calciphylaxis 10/20/2016
Madrigal Announces The Initiation Of A Phase II Study Of MGL-3196 In Patients With Non-Alcoholic Steatohepatitis (NASH) 10/20/2016
Omeros (OMER) Announces Positive Data From OMS721 Phase II Trial In Patients With Stem Cell Transplant-Associated Thrombotic Microangiopathy 10/20/2016
Tobira (TBRA) Announces Late-Breaking Oral Presentation Of CENTAUR Phase IIb Trial Results At The American Academy For The Study Of Liver Diseases Annual Meeting 10/20/2016
Gilead (GILD)'s GS-4997 Meets Goals in Mid-Stage NASH Trial, But Flunks Studies In PAH And DKD 10/20/2016